Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV

J Acquir Immune Defic Syndr. 2006 May;42(1):131-3. doi: 10.1097/01.qai.0000209911.10071.18.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Drug Resistance, Viral / genetics
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / prevention & control
  • HIV Infections / transmission
  • HIV Protease / genetics
  • HIV-1 / drug effects
  • HIV-1 / genetics*
  • Humans
  • Infant
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical
  • Lamivudine / pharmacology
  • Lamivudine / therapeutic use*
  • Mutation*
  • Nevirapine / pharmacology
  • Nevirapine / therapeutic use*
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Complications, Infectious / virology
  • RNA-Directed DNA Polymerase / genetics
  • Reverse Transcriptase Inhibitors / pharmacology
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Rwanda
  • Selection, Genetic*
  • Species Specificity
  • Treatment Outcome
  • Uganda

Substances

  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Nevirapine
  • RNA-Directed DNA Polymerase
  • HIV Protease